Introduction
tumor, ANL, tumor-related deaths, lung cancer, HCC
HEPATOCELLULAR CARCINOMA, TUMOR, OF PRIMARY LIVER CANCER, LUNG CANCER
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, accounting for 90% of primary liver cancers. China has a high incidence of HCC, accounting for more than half of the new cases in the world each year, and ranks second only to lung cancer in tumor-related deaths.Common treatments for HCC include tumor resection, liver transplantation, transarterial chemoembolization, radiotherapy and molecular targeted drug therapy.Sorafenib is the first drug approved for the treatment of HCC, and both the SHARP study and Oriental study have confirmed that sorafenib can significantly prolong the survival of patients with advanced HCC. In the SHARP study of Westerners, the median overall survival (mOS) of sorafenib alone was 10.7 monthsStudies have shown that anlotinib (ANL) is effective and well tolerated as a treatment for patients with advanced HCC.The purpose of this study was to explore the safety and efficacy of ANL alone or in combination with Tigio (S-1) in the treatment of advanced HCC.